Updates on Belamaf in Multiple Myeloma: ASH 2023 Highlights

Explore the latest findings from the American Society of Hematology (ASH) 2023 Hybrid Congress regarding Belamaf in multiple myeloma, including real-world outcomes, safety and efficacy analyses, long-term treatment impacts, infection risk, ocular toxicity prevention, and more. Key presentations cove

0 views • 35 slides